Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Boosted protease inhibitor and lamivudine provides effective maintenance treatment

HIV maintenance treatment with two drugs, a boosted protease inhibitor and lamivudine, is just as effective as three-drug treatment with a boosted protease inhibitor in people who

Published
26 October 2017
By
Keith Alcorn
HIV Regimen Switch May Contribute to Weight Gain

According to results of a study presented at IDWeek 2017, an increase in body weight is common in HIV patients who are switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to an integrase strand transfer inhibitor.

Published
09 October 2017
From
Monthly Prescribing Reference
Maraviroc matches boosted protease inhibitor treatment over 96 weeks

Treatment with maraviroc (Celsentri/Selzentry) is associated with durable HIV suppression and a favourable lipid profile, investigators report in HIV Medicine. The 96-week randomised study compared

Published
11 September 2017
By
Michael Carter
No evidence of reduced efficacy or increased side-effects when patients switch to generic drugs, comparison study finds

An analysis of 440 people switched to generic antiretroviral drugs at an Italian clinic and a matched cohort of patients who remained on their branded medication has

Published
24 August 2017
By
Roger Pebody
Terrence Higgins Trust and BHIVA advise on the use of generic HIV antiretroviral therapy

We believe that people living with HIV should be at the heart of decisions made about their care. Therefore decisions around switching to generic HIV medication should be based on a full discussion between a person living with HIV and their HIV clinician.

Published
16 August 2017
From
Terrence Higgins Trust
Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease

Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir was associated with lipid reductions in people with HIV at higher risk of heart

Published
09 August 2017
By
Keith Alcorn
HIV: A therapeutic advance for resource-limited settings

ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa, shows that dual therapy with lamivudine and a boosted protease inhibitor is effective as second-line treatment in patients infected by HIV with multiple mutations. Such treatment deescalation will reduce costs, side effects, and the need for virological monitoring of patients. The results of this study are published in The Lancet HIV.

Published
31 May 2017
From
Eurekalert Inf Dis
Switching from efavirenz to lopinavir/ritonavir has no meaningful impact on neurological function, says UK study

Switching from efavirenz does not significantly improve the neurological function of patients taking virologically suppressive antiretroviral therapy, investigators from the UK report in HIV Medicine. The

Published
10 May 2017
By
Michael Carter
A quarter of people with second-line ART treatment failure in Kenya have exhausted current treatment options

Affordable third-line antiretrovirals are urgently needed in resource-limited settings, according to research conducted in Kenya and published in the online edition of AIDS. The study showed that

Published
25 April 2017
By
Michael Carter
Switching from Atripla to generic-containing regimens can produce large cost savings

Switching from branded Atripla to regimens that include at least one generic drug formulation can achieve big cost savings without compromising virological efficacy, according to research from Brighton presented

Published
23 April 2017
By
Michael Carter
← First12345...28Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.